Morgan Stanley’s Top Healthcare Stock Holdings: JNJ, ISRG, BMY, PFE, ABT

Wall St. Watchdog reveals information regarding Morgan Stanley’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 400 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $9.567 billion.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, Morgan Stanley reported holding 0 shares. On 09/30/2011, Morgan Stanley reported holding 13,603,271 shares with a market value of $866,392,311. This comprised 0.58% of the total portfolio. The net change in shares for this position over the two quarters is 13,603,271. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Intuitive Surgical Inc. (NASDAQ:ISRG): On 06/30/2011, Morgan Stanley reported holding 0 shares. On 09/30/2011, Morgan Stanley reported holding 1,634,307 shares with a market value of $595,345,352. This comprised 0.4% of the total portfolio. The net change in shares for this position over the two quarters is 1,634,307. About Company: Intuitive Surgical, Inc. design, manufactures and markets surgical systems. The Company’s surgical system controls Intuitive Surgical endoscopic instruments, including rigid endoscopes, blunt and sharp endoscopic dissectors, scissors, scalpels, forceps/pickups, needle holders, endoscopic retractors, electrocautery, ultrasonic cutters, and accessories during surgical procedures.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, Morgan Stanley reported holding 14,604,770 shares with a market value of $422,954,126. This comprised 0.69% of the total portfolio. On 09/30/2011, Morgan Stanley reported holding 17,664,991 shares with a market value of $554,327,403. This comprised 0.37% of the total portfolio. The net change in shares for this position over the two quarters is 3,060,221. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, Morgan Stanley reported holding 0 shares. On 09/30/2011, Morgan Stanley reported holding 27,826,738 shares with a market value of $491,976,736. This comprised 0.33% of the total portfolio. The net change in shares for this position over the two quarters is 27,826,738. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, Morgan Stanley reported holding 9,196,442 shares with a market value of $483,916,768. This comprised 0.79% of the total portfolio. On 09/30/2011, Morgan Stanley reported holding 8,910,769 shares with a market value of $455,696,721. This comprised 0.31% of the total portfolio. The net change in shares for this position over the two quarters is -285,673. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Forest Laboratories Inc. (NYSE:FRX): On 06/30/2011, Morgan Stanley reported holding 10,208,518 shares with a market value of $401,603,100. This comprised 0.66% of the total portfolio. On 09/30/2011, Morgan Stanley reported holding 14,468,957 shares with a market value of $445,499,199. This comprised 0.3% of the total portfolio. The net change in shares for this position over the two quarters is 4,260,439. About Company: Forest Laboratories, Inc. develops, manufactures, and sells both branded and generic forms of ethical products which require a physician’s prescription. The Company also manufactures non-prescription pharmaceutical products sold over-the-counter, which are used for the treatment of a wide range of illnesses. Forest’s products are marketed in the United States and eastern Europe.
  • Illumina Inc. (NASDAQ:ILMN): On 06/30/2011, Morgan Stanley reported holding 0 shares. On 09/30/2011, Morgan Stanley reported holding 9,772,140 shares with a market value of $399,875,951. This comprised 0.27% of the total portfolio. The net change in shares for this position over the two quarters is 9,772,140. About Company: Illumina, Inc. develops, manufactures and markets integrated systems for the large scale analysis of genetic variation and biological function. The Company provides a comprehensive line of products and services that currently serve the sequencing, genotyping and gene expression markets for genomic research centers, pharmaceutical companies, academic institutions and biotechnology companies.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, Morgan Stanley reported holding 0 shares. On 09/30/2011, Morgan Stanley reported holding 11,538,850 shares with a market value of $377,320,404. This comprised 0.25% of the total portfolio. The net change in shares for this position over the two quarters is 11,538,850. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, Morgan Stanley reported holding 0 shares. On 09/30/2011, Morgan Stanley reported holding 6,813,564 shares with a market value of $314,241,564. This comprised 0.21% of the total portfolio. The net change in shares for this position over the two quarters is 6,813,564. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Valeant Pharmaceuticals International (NYSE:VRX): On 06/30/2011, Morgan Stanley reported holding 0 shares. On 09/30/2011, Morgan Stanley reported holding 7,536,267 shares with a market value of $279,746,223. This comprised 0.19% of the total portfolio. The net change in shares for this position over the two quarters is 7,536,267. About Company: Valeant Pharmaceuticals International, Inc. develops and distributes drugs. The Company develops drugs for unmet medical needs in central nervous system disorders; and distributes generic and branded generic drugs in Latin America and Eastern Europe.

(Note: Data regarding Morgan Stanley’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>